Kohn, Christine G <br/><br/>
Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Apr 2017 
 - 1194-1202 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2016.69.6336  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Carboplatin--administration & dosage<br/>Cell Cycle Checkpoints<br/>Clinical Trials, Phase III as Topic<br/>Cost-Benefit Analysis<br/>Dacarbazine--administration & dosage<br/>Disease-Free Survival<br/>Drug-Related Side Effects and Adverse Reactions--economics<br/>Health Care Costs--statistics & numerical data<br/>Humans<br/>Ipilimumab<br/>Markov Chains<br/>Melanoma--drug therapy<br/>Models, Economic<br/>Nivolumab<br/>Paclitaxel--administration & dosage<br/>Proto-Oncogene Proteins B-raf--genetics<br/>Quality-Adjusted Life Years<br/>Randomized Controlled Trials as Topic<br/>Survival Rate